HALO
Halozyme Therapeutics, Inc.
Biotechnology · Healthcare · United States
100.67
close · 2026-08-13
value
54
cheaper than peers54
quality
80
stronger fundamentals80
ranked against
Biotechnology (commercial)
value
quality
101 peerswide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 9.69× | 88 |
| price to sales | 7.32× | 67 |
| EV to EBITDA | 12.99× | 61 |
| price to book | 79.96× | 4 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 173.7% | 99 |
| operating margin | 59.8% | 98 |
| revenue growth | 47.7% | 60 |
| debt to equity | 1517.7% | 3 |
4 of 4 measures available
Facts
| market cap | $11B |
| free cash flow | $337.3M |
| employees | 423 |
| first trade | 2004-03-16 |
| next earnings | 2026-08-06 |
| fundamentals updated | 2026-08-10 |